GE Vernova Inc.
GE Vernova Inc. (GEV) Stock News
The latest GEV headlines and market coverage — 3 recent stories, updated throughout the day.
- The Motley Fool·
I'm Calling It: GE Vernova (GEV) Is a Buy Before This Catalyst Drops
GE Vernova, spun off from General Electric two years ago, has surged nearly 750% since its market debut. The company operates in Power, Electrification, and Wind segments and is positioned to benefit from the 'AI grid supercycle' driven by hyperscalers and AI infrastructure providers. With a $163 billion backlog and projected revenue growth of 16% CAGR through 2028, analysts view the stock as fairly valued at 36x earnings despite its strong growth prospects.
- Benzinga·
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals reported positive Phase 3 clinical data for CASGEVY in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. All evaluated patients achieved primary endpoints with sustained clinical benefits and a consistent safety profile. The company is pursuing FDA approval to expand the therapy's use to younger children.
- Benzinga·
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent with results previously observed in adolescent and adult patients. Phase 3 Studies Show High Rates Of Clinical Response An interim analysis from the Phase 3 CLIMB-151 study in children with severe SCD showed all 11 treated patients remained free from vaso-occlusive crises (VOCs). data-variant="card" data-news-mode="manual" > Read Also: Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps Among the eight patients with sufficient follow-up, 100% achieved the primary endpoint of remaining VOC-free for at least 12 ... Full story available on Benzinga.com